Brokerages Set Zoetis Inc. (NYSE:ZTS) Price Target at $200.88

Key Points

• Zoetis Inc. has received an average recommendation of "Moderate Buy" from analysts, with four hold ratings and five buy ratings among nine brokerages.
• The company's earnings for the recent quarter were reported at $1.76 EPS, exceeding expectations of $1.62 EPS, alongside a revenue of $2.46 billion.
• Institutional investors own 92.80% of Zoetis stock, with significant purchases from major firms like Norges Bank and Nuveen LLC this year.

Shares of Zoetis Inc. (NYSE:ZTS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $200.8750.

A number of brokerages have recently issued reports on ZTS. Argus reaffirmed a "buy" rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th.

Zoetis Trading Down 0.9%

Zoetis stock traded down $1.28 during trading hours on Friday, reaching $145.82. The company had a trading volume of 4,455,824 shares, compared to its average volume of 2,375,084. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The company has a 50-day moving average price of $151.25 and a 200 day moving average price of $156.52. The firm has a market cap of $64.63 billion, a price-to-earnings ratio of 25.10, a P/E/G ratio of 2.34 and a beta of 0.88. Zoetis has a 12-month low of $139.70 and a 12-month high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business's revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis will post 6.07 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Portside Wealth Group LLC increased its holdings in Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after purchasing an additional 6,672 shares during the period. Tandem Investment Advisors Inc. raised its holdings in Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after purchasing an additional 198,089 shares during the period. Flagship Harbor Advisors LLC raised its holdings in Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after purchasing an additional 1,760 shares during the period. Horizon Financial Services LLC acquired a new position in shares of Zoetis during the first quarter valued at approximately $380,000. Finally, Sage Rhino Capital LLC grew its position in shares of Zoetis by 117.6% in the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after purchasing an additional 3,791 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.